Scientists have slowed the progression of Huntington’s disease for the first time with a “groundbreaking” new treatment.
Scientists have slowed the progression of Huntington’s disease for the first time with a “groundbreaking” new treatment.
After 36 months, patients treated with high dose AMT-130 saw a 75% slowing of disease progression vs the external control.
The gene therapy company uniQure has announced top-level data from its trial of AMT-130, a new gene therapy designed to treat ...
PsyPost on MSN
Scientists discover a key mechanism for dopamine to regulate brain activity and movement
A new study published in Brain Sciences provides evidence that dopamine promotes movement by directly altering the excitability of key neurons in the brain’s motor circuitry. The research identifies a ...
A global clinical trial for a new Huntington's disease treatment has posted positive results today, announced by trial sponsor uniQure and UCL ...
Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by ...
Discover Alector's latest breakthroughs in neurodegenerative disease therapies, including updates on Alzheimer's and Parkinson's programs.
Global Sumud Flotilla reports harassment near Greece; UN calls for a probe as European ships move to safeguard civilians at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback